|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date31 Oct 2017 |
EGFR Mutation Blood Test Evaluation and Assessment of Changes in Sensitivity Resulting from Initiation of FirstLine Treatment of Advanced Adenocarcinoma of the Lung Diagnostic (EMERALD) Study
100 Clinical Results associated with AstraZeneca Pty Ltd.
0 Patents (Medical) associated with AstraZeneca Pty Ltd.
100 Deals associated with AstraZeneca Pty Ltd.
100 Translational Medicine associated with AstraZeneca Pty Ltd.